ArTS Archivio della ricerca di Trieste

FEDERICO, STEPHANIE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.581
EU - Europa 4.727
AS - Asia 4.143
SA - Sud America 521
AF - Africa 168
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 13
AN - Antartide 1
Totale 19.174
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.418
SG - Singapore 1.530
IT - Italia 989
CN - Cina 943
SE - Svezia 812
PL - Polonia 518
BR - Brasile 416
DE - Germania 382
HK - Hong Kong 370
VN - Vietnam 368
NL - Olanda 352
FR - Francia 341
UA - Ucraina 278
KR - Corea 260
GB - Regno Unito 239
FI - Finlandia 201
RU - Federazione Russa 192
IN - India 158
TR - Turchia 137
IE - Irlanda 104
CA - Canada 86
BG - Bulgaria 78
BD - Bangladesh 58
JP - Giappone 51
BE - Belgio 45
MA - Marocco 42
IQ - Iraq 41
AT - Austria 38
ID - Indonesia 36
CH - Svizzera 35
ES - Italia 35
CZ - Repubblica Ceca 32
AR - Argentina 31
PK - Pakistan 25
MX - Messico 24
CI - Costa d'Avorio 23
MY - Malesia 22
EC - Ecuador 20
EG - Egitto 20
SA - Arabia Saudita 20
ZA - Sudafrica 20
UZ - Uzbekistan 18
CO - Colombia 17
IL - Israele 16
AU - Australia 15
LT - Lituania 14
AZ - Azerbaigian 12
KE - Kenya 12
EU - Europa 11
JM - Giamaica 11
VE - Venezuela 11
CL - Cile 10
JO - Giordania 10
BZ - Belize 9
PH - Filippine 9
AE - Emirati Arabi Uniti 8
DZ - Algeria 8
IR - Iran 8
NG - Nigeria 7
SN - Senegal 7
TG - Togo 7
TN - Tunisia 7
HN - Honduras 6
PE - Perù 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
NZ - Nuova Zelanda 5
PT - Portogallo 5
TH - Thailandia 5
AL - Albania 4
BB - Barbados 4
BY - Bielorussia 4
CR - Costa Rica 4
ET - Etiopia 4
HU - Ungheria 4
KZ - Kazakistan 4
OM - Oman 4
PR - Porto Rico 4
RS - Serbia 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
BO - Bolivia 3
GR - Grecia 3
LV - Lettonia 3
MN - Mongolia 3
NO - Norvegia 3
PY - Paraguay 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
DK - Danimarca 2
GE - Georgia 2
KG - Kirghizistan 2
KW - Kuwait 2
PA - Panama 2
PS - Palestinian Territory 2
RO - Romania 2
SI - Slovenia 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
Totale 19.146
Salva come PNG Salva come JPEG
Città #
Dallas 2.468
Singapore 976
Ashburn 633
Houston 599
Woodbridge 595
Fairfield 591
Ann Arbor 447
Warsaw 430
San Jose 391
Chandler 351
Hong Kong 350
Hefei 331
Wilmington 300
Trieste 298
Jacksonville 264
Seattle 260
Seoul 249
Amsterdam 228
Cambridge 218
Beijing 203
Princeton 133
Munich 131
Boardman 130
Columbus 113
The Dalles 108
Izmir 107
Chicago 101
Los Angeles 95
Ho Chi Minh City 92
Dublin 90
Hanoi 87
Lauterbourg 84
Santa Clara 84
London 83
Buffalo 80
Sofia 77
Zgierz 74
New York 73
Moscow 67
Helsinki 62
Frankfurt am Main 59
Council Bluffs 58
Menlo Park 58
Milan 56
São Paulo 48
North Bergen 42
Shanghai 42
West Jordan 41
Turku 39
Mestre 37
Düsseldorf 36
Brussels 35
Rome 35
Guangzhou 33
San Diego 33
Tokyo 30
Verona 29
Toronto 28
Sacile 26
Vienna 26
Casablanca 25
Abidjan 23
Da Nang 23
Bremen 22
Phoenix 22
Brooklyn 21
Falls Church 21
Brno 20
Chennai 20
Haiphong 20
Montreal 20
Redwood City 20
Orem 19
Bern 18
Nuremberg 18
Dhaka 17
Pittsburgh 16
New Delhi 15
Tashkent 15
Mumbai 14
Zurich 14
Fremont 13
Jakarta 13
Rio de Janeiro 13
Cairo 12
Camerino 12
Codroipo 12
Des Moines 12
Manchester 12
Philadelphia 12
Poplar 12
Torre Del Greco 12
Udine 12
Baghdad 11
Nairobi 11
Norwalk 11
Padova 11
Redondo Beach 11
Tappahannock 11
Atlanta 10
Totale 13.470
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]-1,3,5-triazine nucleus: a possible template for adenosine receptor subtypes. 851
[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A3 adenosine receptor subtype 750
[1,2,4]Triazolo[1,5-a][1,3,5]Triazine Derivatives as Antagonists for the Adenosine Receptors: a Preliminary Study on Affinity at the A3 Subtype 691
1,2,4]Triazolo[1,5-c]pyrimidines as New Potent Human A3 Adenosine Receptor Antagonists. 671
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 643
[1,2,4]Triazolo[1,5-c]pyrimidine Nucleus as Adenosine Receptor Antagonists: Shift in Selectivity from A2A to A3 Adenosine Receptors. 625
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines 612
The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives 434
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment 432
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition 383
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 341
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 278
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5- c ]pyrimidines to explore the antagonist profiling on adenosine receptors: A preliminary structure-activity relationship study 275
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 275
Advances in Computational Techniques to Study GPCR-Ligand Recognition 263
null 245
Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 δinhibitors 241
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 232
Chemical probes for the adenosine receptors 231
N8-Isopentyl and N8-Phenylethyl Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives as Adenosine Receptor Antagonists 226
Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases 225
Mixed-reversible and covalent kinase inhibition as a possible new strategy to treat neuro-inflammatory/degenerative diseases 225
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems 219
null 217
A facile and novel synthesis of N2-, C6-substituted pyrazolo[3,4- d ]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists 217
null 214
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View? 211
Structural investigations on a novel class of 1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptor antagonists. 210
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonists as a potential anti-Parkinson multitarget approach. 205
Chapter 1: A3 adenosine receptor ligands in the treatment of inflammation and cancer 205
Design, synthesis and evaluation of new indolylpyrimidylpiperazines for gastrointestinal cancer therapy 201
null 197
"Dual Anta-Inhibitors" of the A(2A) Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 187
5-Alkylamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines. Influence of the Substituent on the Affinity at the Adenosine Receptor Subtypes 176
Adenosine Receptor Ligands, Probes, and Functional Conjugates: A 20-Year History of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidines (PTP) 176
Discovery of simplified N2-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies 175
A Computational Workflow for the Identification of Novel Fragments Acting as Inhibitors of the Activity of Protein Kinase CK1δ 172
Novel fluorescent hA3 adenosine receptor antagonists. 171
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example 171
The A3 adenosine receptor as multifaceted therapeutic Target: pharmacology, medicinal Chemistry, and In silico approaches 165
Conjugable A3 Adenosine Receptor Antagonists: Probing the 5 Position of the Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Scaffold. 163
null 161
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective 158
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptor antagonists: new insights into structure affinity relathionship and receptor antagonist recognition. 158
Synthesis and biological evaluation of a new series of 1,2,4-Triazolo(1,5-a)-1,3,5-triazines as human A2A adenosine receptor antagonists with improved water solubility 156
Fluorescent ligands for the A3 adenosine receptor. 155
The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy 155
null 154
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 153
null 153
Anticonvulsivanti 153
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists. 151
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists. 148
Structural Investigations on a Novel Class of [1,2,4]Triazolo[1,5-c]pyrimidines as Adenosine Receptor Antagonists. 148
Conjugable A3 adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes 144
null 140
Fluorescent ligands for adenosine receptors 138
Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. 138
Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A2A Adenosine Receptor Antagonists 138
CVT 6975-like Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine Derivatives: an Attempt towards A2B Adenosine Receptor Affinity. 136
Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2Aligand binding kinetics 135
Novel fluorescent antagonist as a molecular probe in A3 adenosine receptor binding assays using flow cytometry. 134
Exploring the Directionality of 5-Substitutions in a New Series of 5-Alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptor Antagonists. 133
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta 130
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 130
Simplification of Pyrazolo-triazolo-pyrimidine Nucleus for Searching New Adenosine Receptor Antagonists. 129
Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors 126
7-Amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines as CK1δ inhibitors: Exploring substitutions at the 2 and 5-positions 125
BIOMEDICAL APPLICATIONS I: DELIVERY OF DRUGS 124
Pyrazolo-triazolo-pyrimidine Scaffold as a Molecular Passepartout for the Pan-Recognition of Human Adenosine Receptors 122
Does the combination of optimal substitutions at the C(2)-, N(5)- and N(8)-positions of the pyrazolo-triazolo-pyrimidine scaffold guaranteee selective modulation of the human A(3) adenosine receptors? 121
Exploring Directionality of 5-Substitutions in a New Series of 5-Alkyamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a Strategy to Design Novel Human A3 Adenosine Receptors Antagonists. 120
null 116
Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A(3) adenosine receptor antagonists 115
null 112
Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis 105
FLUORESCENT ANTAGONISTS OF THE A3 ADENOSINE RECEPTOR 103
Functionalized ligands targeting G protein-coupled adenosine receptors 102
Recent developments in the field of non peptidic alpha-v beta3 antagonists 101
null 99
Promising Targets and Strategies to Control Neuroinflammation (Part II) 97
null 97
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective? 94
null 93
Promising Targets and Strategies to Control Neuroinflammation (Part I) 91
null 89
Acyclic purine and pyrimidine nucleotide analogs as ecto-5′-nucleotidase (CD73) inhibitors 88
Synthesis and pharmacological characyerization of a new series of 5,7-disubstituted [1,2,4]triazolo[1,5-a] [1,3,5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand receptor recognition process. 75
Potent and selective A3adenosine receptor antagonists bearing aminoesters as heterobifunctional moieties 75
null 70
null 70
Combining selectivity and affinity predictions using an integrated support vector machine (SVM) approach: A novel tool to discriminate between the human A2A and A3 receptor bonding sites 65
Pyrazolo derivatives as potent adenosine receptor antagonists: An overview on the structure-activity relationships 65
null 63
null 63
Targeting G Protein-Coupled Receptors with Magnetic Carbon Nanotubes: The Case of the A3 Adenosine Receptor 62
Human A3 adenosine receptor as versatile G protein coupled receptor example to validate the receptor homology modeling technology. 60
null 59
Exploring potency and selectivity receptor antagonist profiles using a multilabe classification approach: the human adenosine receptor as a key study 57
Receptor Driven Identifications of Novel Human A3 adenosine receptor antagonists as Potential therapeutic agents. 56
Totale 19.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021316 0 0 0 0 0 0 0 0 0 121 71 124
2021/20221.105 94 100 55 234 19 48 45 28 101 128 46 207
2022/20231.304 118 179 108 178 112 236 9 104 154 28 57 21
2023/20241.086 59 74 70 75 72 92 155 232 4 71 86 96
2024/20252.706 100 107 342 219 191 195 156 133 305 323 210 425
2025/20267.435 665 1.050 2.260 520 373 387 750 195 635 600 0 0
Totale 19.615